Vaping firms should pay more attention to older smokers, argue Neil McKeganey, Gabe Barnard and Andrea Patton. Read More
Banning e-liquid flavors may not achieve the outcomes that proponents of that measure have in mind.Read More
Manufacturers must show the benefit of pouches and quantify underage usage. Read More
Making e-cigarettes available only on prescription may be a net negative for public health, writes Neil McKeganey. Read More
FDA’s reluctance to permit flavors may hinder conversions to less harmful products.Read More
After rooting out ENDS flavors, regulators may turn their attention to flavor names, writes Neil McKeganey.Read More
The FDA used questionable statistics to justify its marketing denial, says Neil McKeganey.Read More
Neil McKeganey explains how companies can make the most of a recent ruling forcing the FDA to reconsider MDOs. Read More
Neil McKeganey and Christopher Russell of the Centre for Substance Use Research in Glasgow, Scotland, have cautioned against a “new McCarthyism” in the area of e-cigarette research. Read More
